GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » Cyclically Adjusted Revenue per Share

Silence Therapeutics (Silence Therapeutics) Cyclically Adjusted Revenue per Share : $0.24 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Silence Therapeutics's adjusted revenue per share for the three months ended in Dec. 2023 was $0.023. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.24 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Silence Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-20), Silence Therapeutics's current stock price is $7.00. Silence Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.24. Silence Therapeutics's Cyclically Adjusted PS Ratio of today is 29.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Silence Therapeutics was 142.14. The lowest was 2.31. And the median was 15.00.


Silence Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Silence Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Cyclically Adjusted Revenue per Share Chart

Silence Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.18 0.21 0.24

Silence Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.24 0.26 0.25 0.24

Competitive Comparison of Silence Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Silence Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Cyclically Adjusted PS Ratio falls into.



Silence Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Silence Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.023/130.5000*130.5000
=0.023

Current CPI (Dec. 2023) = 130.5000.

Silence Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200712 0.000 84.500 0.000
200806 0.000 86.600 0.000
200812 0.000 87.100 0.000
200906 0.000 88.100 0.000
200912 0.000 88.900 0.000
201006 0.000 90.200 0.000
201012 0.000 91.700 0.000
201106 0.000 93.500 0.000
201112 0.000 95.000 0.000
201206 0.000 95.600 0.000
201212 0.000 97.300 0.000
201306 0.000 98.000 0.000
201312 0.000 99.200 0.000
201406 0.000 99.800 0.000
201412 0.000 99.900 0.000
201506 0.000 100.100 0.000
201512 0.000 100.400 0.000
201606 0.000 101.000 0.000
201612 0.000 102.200 0.000
201706 0.000 103.500 0.000
201712 0.000 105.000 0.000
201806 0.000 105.900 0.000
201812 0.000 107.100 0.000
201906 0.000 107.900 0.000
201912 0.000 108.500 0.000
202006 0.000 108.800 0.000
202009 0.031 109.200 0.037
202012 0.038 109.400 0.045
202103 0.050 109.700 0.059
202106 0.042 111.400 0.049
202109 0.048 112.400 0.056
202112 0.051 114.700 0.058
202203 0.084 116.500 0.094
202206 0.050 120.500 0.054
202209 0.039 122.300 0.042
202212 0.054 125.300 0.056
202303 0.128 126.800 0.132
202306 0.106 129.400 0.107
202309 0.031 130.100 0.031
202312 0.023 130.500 0.023

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Silence Therapeutics  (OTCPK:SLNCF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Silence Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.00/0.24
=29.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Silence Therapeutics was 142.14. The lowest was 2.31. And the median was 15.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Silence Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics (Silence Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.